Lytix Biopharma AS
OSE:LYTIX
Lytix Biopharma AS
Revenue
Lytix Biopharma AS
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
L
|
Lytix Biopharma AS
OSE:LYTIX
|
Revenue
kr4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
64%
|
CAGR 10-Years
N/A
|
|
|
Hofseth Biocare ASA
OSE:HBC
|
Revenue
kr257.4m
|
CAGR 3-Years
43%
|
CAGR 5-Years
31%
|
CAGR 10-Years
29%
|
|
|
B
|
Bergenbio ASA
OSE:BGBIO
|
Revenue
kr848k
|
CAGR 3-Years
3%
|
CAGR 5-Years
-38%
|
CAGR 10-Years
N/A
|
|
|
Arcticzymes Technologies ASA
OSE:AZT
|
Revenue
kr104.4m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
18%
|
CAGR 10-Years
12%
|
|
|
N
|
Nykode Therapeutics ASA
OSE:NYKD
|
Revenue
$3.9m
|
CAGR 3-Years
-74%
|
CAGR 5-Years
279%
|
CAGR 10-Years
N/A
|
|
|
T
|
Thor Medical ASA
OSE:TRMED
|
Revenue
kr0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Lytix Biopharma AS
Glance View
Lytix Biopharma AS develops novel drugs for the treatment of resistant bacterial and fungal infections, as well as oncology treatments. The company is headquartered in Oslo, Oslo. The company went IPO on 2021-06-14. The firm's product, LTX-315, is a oncolytic molecule representing a new and superior in situ therapeutic vaccination principle to boost anti-cancer immunity, with the potential to be the ideal combination partner with other types of immunotherapy. LTX-315 targets cancer cells and disintegrates their cell membranes, causing immunogenic cell death and release of a patient’s tumor specific antigens. This mode of action allows cytotoxic T cells to recognize, infiltrate, and attack cancer cells. The firm serves customers domestically.
See Also
What is Lytix Biopharma AS's Revenue?
Revenue
4m
NOK
Based on the financial report for Dec 31, 2023, Lytix Biopharma AS's Revenue amounts to 4m NOK.
What is Lytix Biopharma AS's Revenue growth rate?
Revenue CAGR 5Y
64%
Over the last year, the Revenue growth was -64%.
You don't have any saved screeners yet